Key Details
Price
$3.11Annual ROE
-220.59%Beta
0.36Events Calendar
Next earnings date:
Apr 1, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Apr 1, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sep 23, 2024Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia
IRVINE, Calif. and CAMBRIDGE, Mass.
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences Third Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-58 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on September 23, 2024.
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024
ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger
ReShape Lifesciences, Inc. (NASDAQ:RSLS ) Q1 2024 Earnings Conference Call on May 15, 2024 at 4:30 PM ET featuring Michael Miller, Paul Hickey, and Thomas Stankovich. Thank you for joining the call. Now I will hand it over to Michael Miller from Rx Communications.
ReShape Lifesciences Inc. (Nasdaq: RSLS), a leading company specializing in weight loss and metabolic health solutions, will release its financial results for the first quarter of 2024 and provide a corporate update on Wednesday, May 15, 2024, after the market closes.
ReShape Lifesciences (NASDAQ: RSLS ) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for a PMA supplement. That a PMA supplement applies to the company's Lap-Band 2.0 FLEX.
ReShape Lifesciences (NASDAQ:RSLS) saw its stock soar, up 41% to 36 cents a share in premarket, after the micro-cap firm's latest obesity treatment, Lap-Band 2.0, was approved by the US Food and Drug Administration (FDA). The FDA provided the company with a PMA supplement approval for the new generation of ReShape's Lap-Band – described as a “minimally invasive alternative to surgical stapling procedures – which features ‘FLEX' technology that the company said acts as a ‘relief valve' allowing larger pieces of food to move more easily through the narrower passage created by the band.
FAQ
- What is the ticker symbol for ReShape Lifesciences?
- Does ReShape Lifesciences pay dividends?
- What sector is ReShape Lifesciences in?
- What industry is ReShape Lifesciences in?
- What country is ReShape Lifesciences based in?
- When did ReShape Lifesciences go public?
- Is ReShape Lifesciences in the S&P 500?
- Is ReShape Lifesciences in the NASDAQ 100?
- Is ReShape Lifesciences in the Dow Jones?
- When was ReShape Lifesciences's last earnings report?
- When does ReShape Lifesciences report earnings?
- Should I buy ReShape Lifesciences stock now?